USPH

SEC source: 0000950170-25-041698 · ownership.xml · nonDerivative · entry 1

HENDRICKSON CAREY P · CIK 0001482760 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,506

F1 · balance_after: Includes 17,938 shares of which 1,714 will vest on each May 20, 2025, August 20, 2025 and November 20, 2025, 1,726 will vest on March 6, 2026, 1,246 will vest on each of May 20, 2026, August 20, 2026 and November 20, 2026, 1,252 will vest on March 6, 2027, 1,012 will vest on each of May 20, 2027, August 20, 2027, November 20, 2027, 1,016 will vest on March 6, 2028, 506 will vest each of May 20, 2028, August 20, 2028, November 20, 2028, and 510 will vest on March 6, 2029, if he is employed on those dates.

SEC source: 0000950170-25-035831 · ownership.xml · nonDerivative · entry 1

REEVE GRAHAM D. · CIK 0001519948 · COO

10b5-1 filing: No plan indicated

Ownership: Indirect · Reeve Trust

Disclosed balance after: 7,168

F1 · shares: All 1,730 shares were sold at the same price of $82.11.

F1 · price: All 1,730 shares were sold at the same price of $82.11.

SEC source: 0000950170-25-028168 · ownership.xml · nonDerivative · entry 1

READING CHRISTOPHER J · CIK 0001270356 · Director · Chairman of the Board and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,088

F1 · shares: These shares of common stock were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 15 equal quarterly installments of 1,265 shares vesting on each of May 20, August 20, November 20 of 2025 and March 6, May 20, August 20 and November 202 in each year 2026, 2027 and 2028, with the final 1,275 shares vesting on March 6, 2029, if he is employed by the Company on those dates.

F2 · balance_after: Includes the shares in footnote 1 and 22,152 shares described in next sentences. On February 24, 2025, the issuer and the reporting person mutually agreed to amend the vesting terms of the outstanding awards. Per the amendment, of the total outstanding unvested shares of 22,152, 2,887 will vest on May 20, 2025, 2,887 will vest on each August 20, 2025 and November 20, 2025, 2,887 will vest on March 6, 2026, 1,637 will vest on each of May 20, 2026, August 20, 2026 and November 20, 2026, and March 6, 2027, 1,012 will vest on each of May 20, 2027, August 20, 2027, November 2027 and 1,020 will vest on March 6, 2028, if he is employed on those dates.

SEC source: 0000950170-25-028170 · ownership.xml · nonDerivative · entry 1

Binstein Richard · CIK 0001919840 · EVP Gen'l Counsel & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,867

F1 · shares: These shares of common stock were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 15 equal quarterly installments of 506 shares vesting on each of May 20, August 20, November 20 and March 6 in each year 2025, 2026, 2027 and 2028, with the final 510 shares vesting on March 6, 2029, if he is employed by the Company on those dates.

F2 · balance_after: Includes the shares noted in footnote 1 and 9,177 shares described in next sentences. On February 24, 2025, the issuer and the reporting person mutually agreed to amend the vesting terms of the outstanding awards. Per the amendment, of the total outstanding unvested shares of 9,177, 1,045 will vest on May 20, 2025, August 20, 2025 and November 20, 2025, 1,048 will vest on March 6, 2026, 740 will vest on each of May 20, 2026, August 20, 2026 and November 20, 2026, 746 will vest on March 6, 2027, 506 will vest on each of May 20, 2027, August 20, 2027, November 2027 and 510 will vest on March 6, 2028, if he is employed on those dates.

SEC source: 0000950170-25-028169 · ownership.xml · nonDerivative · entry 1

Williams Eric Joseph · CIK 0001871391 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,964

F1 · shares: These shares of common stock were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 15 equal quarterly installments of 756 shares vesting on each of May 20, August 20, November 20 and March 6 in each year 2025, 2026, 2027 and 2028, with the final 780 shares vesting on March 6, 2029, if he is employed by the Company on those dates.

F2 · balance_after: Includes the shares noted in footnote 1 and 10,398, shares described in next sentences. On February 24, 2025, the issuer and the reporting person mutually agreed to amend the vesting terms of the outstanding awards. Per the amendment, of the total outstanding unvested shares of 10,398, 1,408 will vest on May 20, 2025, 1,414 will vest on August 20, 2025, 1,130 will vest on November 20, 2025, 1,138 will vest on March 6, 2026, 818 will vest on each of May 20, 2026, August 20, 2026 and November 20, 2026, 826 will vest on March 6, 2027, 506 will vest on each of May 20, 2027, August 20, 2027, November 2027 and 510 will vest on March 6, 2028, if he is employed on those dates.

SEC source: 0000950170-25-028165 · ownership.xml · nonDerivative · entry 1

HENDRICKSON CAREY P · CIK 0001482760 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,569

F1 · shares: These shares of common stock were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 15 equal quarterly installments of 506 shares vesting on each of May 20, August 20, November 20 of 2025 and March 6, May 20, August 20 and November 20 in each year 2026, 2027 and 2028, with the final 510 shares vesting on March 6, 2029, if he is employed by the Company on those dates.

F2 · balance_after: Includes the shares noted in footnote 1 and 9,838 shares described in next sentences. On February 24, 2025, the issuer and the reporting person mutually agreed to amend the vesting terms of the outstanding awards. Per the amendment, of the total outstanding unvested shares of 9,838, 1,208 will vest on May 20, 2025, 1,208 will vest on each August 20, 2025 and November 20, 2025, 1,220 will vest on March 6, 2026, 740 will vest on each of May 20, 2026, August 20, 2026 and November 20, 2026, 746 will vest on March 6, 2027, 506 will vest on each of May 20, 2027, August 20, 2027, November 2027 and 510 will vest on March 6, 2028, if he is employed on those dates.

SEC source: 0000950170-25-028166 · ownership.xml · nonDerivative · entry 1

REEVE GRAHAM D. · CIK 0001519948 · COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,192

F1 · shares: These shares of common stock were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 15 equal quarterly installments of 506 shares vesting on each of May 20, August 20, November 20 and March 6 in each year 2025, 2026, 2027 and 2028, with the final 510 shares vesting on March 6, 2029, if he is employed by the Company on those dates.

F2 · balance_after: Includes the shares noted in footnote 1 and 11,092, shares described in next sentences. On February 24, 2025, the issuer and the reporting person mutually agreed to amend the vesting terms of the outstanding awards. Per the amendment, of the total outstanding unvested shares of 11,092, 1,442 will vest on May 20, 2025, August 20, 2025 and November 20, 2025, 1,458 will vest on March 6, 2026, 818 will vest on each of May 20, 2026, August 20, 2026 and November 20, 2026, 826 will vest on March 6, 2027, 506 will vest on each of May 20, 2027, August 20, 2027, November 2027 and 510 will vest on March 6, 2028, if he is employed on those dates.

SEC source: 0000950170-24-134677 · ownership.xml · nonDerivative · entry 1

HENDRICKSON CAREY P · CIK 0001482760 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,469

F1 · balance_after: Includes 11,046 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 1,209 shares on January 1, 2025, 1,208 shares each on April 1, 2025, July 1, 2025, October 1, 2025; 1,221 shares on January 1, 2026; 740 shares each on April 1, 2026, July 1, 2026, October 1, 2026; 747 shares on January 1, 2027; 506 shares each on April 1, 2027, July 1, 2027, October 1, 2027 and 507 shares on January 2028, if he is a director of the Company on those dates.

SEC source: 0000950170-24-131187 · ownership.xml · nonDerivative · entry 1

Binstein Richard · CIK 0001919840 · EVP Gen'l Counsel & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,767

F1 · balance_after: Includes 10,417 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 1,241 shares on January 1, 2025; 1,045 shares on each April 1, 2025, July 1, 2025, and on October 1, 2025; 1,049 shares on January 1, 2026; 740 shares on each of April 1, 2026, July 1, 2026, October 1, 2026; 747 shares on January 1, 2027; and 506 shares on each of April 1, 2027, July 1, 2027, October 1, 2027; and 507 shares on January 1, 2028, if he is an employee of the Company on those dates.

SEC source: 0000950170-24-126535 · ownership.xml · nonDerivative · entry 1

Harris Bernard A Jr · CIK 0001337906 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,726

F1 · price: The price reported ($92.95) is the weighted average price. The shares were sold in multiple transactions at prices ranging from $92.87 to $93.01 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 712 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 356 shares in each of January 1, 2025 and April 1, 2025, if he is a director of the Company on those dates.

SEC source: 0000950170-24-125740 · ownership.xml · nonDerivative · entry 1

HAM NANCY · CIK 0001124500 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,112

F1 · price: The price reported ($96.72) is weighted average price. The shares were sold in multiple transactions at prices ranging from $96.68 to $96.81 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 712 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 356 shares in each of January 1, 2025 and April 1, 2025, if she is a director of the Company on those dates.

SEC source: 0000950170-24-125738 · ownership.xml · nonDerivative · entry 1

Williams Eric Joseph · CIK 0001871391 · Co-Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,814

F1 · price: The price reported ($95.84)is weighted average price. The shares were sold in multiple transactions at prices ranging from $95.83 to $95.84 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 11,806 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 1,409 shares on January 1, 2025; 1,408 shares on April 1, 2025, 1,414 shares on July 1, 2025, 1,130 on October 1, 2025; 1,139 shares on January 1, 2026; 818 shares on each of April 1, 2026, July 1, 2026, October 1, 2026; 827 shares on January 1, 2027; and 506 shares on each of April 1, 2027, July 1, 2027, October 1, 2027; and 507 shares on January 1, 2028, if he is an employee of the Company on those dates.

SEC source: 0000950170-24-125739 · ownership.xml · nonDerivative · entry 1

REEVE GRAHAM D. · CIK 0001519948 · COO

10b5-1 filing: No plan indicated

Ownership: Indirect · Reeve Trust

Disclosed balance after: 7,106

SEC source: 0000950170-24-125737 · ownership.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,424

F1 · price: The price reported ($95.78) is the weighted average price. The shares were sold in multiple transactions at prices ranging from $95.15 to $96.84 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 712 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as 356 share in each of January 1, 2025 and April 1, 2025, if he is a director of the Company on those dates.

SEC source: 0000950170-24-103046 · ownership.xml · nonDerivative · entry 1

Gilmartin Kathleen A · CIK 0001741732 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,904

F1 · price: The price reported $86.09 is the weighted average price. The shares were purchased in multiple transactions at prices ranging from $85.93 to $86.17 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 1,068 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 356 shares on October 1, 2024, January 1, 2025 and April 1, 2025, if she is a member of the Board of Directors of the Company on those dates.

SEC source: 0000950170-24-099579 · ownership.xml · nonDerivative · entry 1

REEVE GRAHAM D. · CIK 0001519948 · COO

10b5-1 filing: No plan indicated

Ownership: Indirect · Reeve Trust

Disclosed balance after: 7,038

F1 · price: The reported price is the weighted average price. The reporting person undertakes to provide to U.S. Physical Therapy Inc., any of its shareholders or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold each at each separate price on this footnote Form 4.

SEC source: 0000950170-24-067492 · ownership.xml · nonDerivative · entry 1

READING CHRISTOPHER J · CIK 0001270356 · Director · Chairman of the Board and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,838

F1 · price: The price reported ($100.26) is the weighted average price. The shares were sold in multiple transactions at prices ranging from $100.00 to $100.90 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 32,913 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 3,587 shares on each of July 1, 2024 and October 1, 2024; 3,588 shares on January 1, 2025; 2,887 shares on each April 1, 2025, July 1, 2025, and on October 1, 2025; 2,888 shares on January 1, 2026; 1,637 shares on each of April 1, 2026, July 1, 2026, October 1, 2026; 1,638 shares on January 1, 2027; and 1,012 shares on each of April 1, 2027, July 1, 2027, October 1, 2027; and 1,017 shares on January 1, 2028, if he is an Officer of the Company on those dates.

SEC source: 0000950170-24-066088 · ownership.xml · nonDerivative · entry 2

READING CHRISTOPHER J · CIK 0001270356 · Director · Chairman of the Board and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,738

F1 · price: For the transaction executed on May 28, 2024, the price reported ($102.13) is the weighted average price. The shares were sold in multiple transactions at prices ranging from $102.00 to $102.26 per share, both inclusive. For the transaction executed on May 29, 2024, the price reported ($100.13) is the weighted average price. The shares were sold in multiple transactions at prices ranging from $100.00 to $100.49 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 32,913 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 3,587 shares on each of July 1, 2024 and October 1, 2024; 3,588 shares on January 1, 2025; 2,887 shares on each April 1, 2025, July 1, 2025, and on October 1, 2025; 2,888 shares on January 1, 2026; 1,637 shares on each of April 1, 2026, July 1, 2026, October 1, 2026; 1,638 shares on January 1, 2027; and 1,012 shares on each of April 1, 2027, July 1, 2027, October 1, 2027; and 1,017 shares on January 1, 2028, if he is an Officer of the Company on those dates.

SEC source: 0000950170-24-066088 · ownership.xml · nonDerivative · entry 1

READING CHRISTOPHER J · CIK 0001270356 · Director · Chairman of the Board and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,738

F1 · price: For the transaction executed on May 28, 2024, the price reported ($102.13) is the weighted average price. The shares were sold in multiple transactions at prices ranging from $102.00 to $102.26 per share, both inclusive. For the transaction executed on May 29, 2024, the price reported ($100.13) is the weighted average price. The shares were sold in multiple transactions at prices ranging from $100.00 to $100.49 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0000950170-24-063209 · ownership.xml · nonDerivative · entry 1

Swanson Regg E. · CIK 0001412473 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,304

F1 · shares: Includes 1,424 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 356 shares on July 1, 2024, October 1, 2024, January 1, 2025 and April 1, 2025, if he is a director of the Company on those dates.

SEC source: 0000950170-24-063207 · ownership.xml · nonDerivative · entry 1

Motsenbocker Anne · CIK 0001904253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,624

F1 · shares: Includes 1,424 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 356 shares on July 1, 2024, October 1, 2024, January 1, 2025 and April 1, 2025, if he is a director of the Company on those dates.

SEC source: 0000950170-24-063192 · ownership.xml · nonDerivative · entry 1

Harris Bernard A Jr · CIK 0001337906 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,726

F1 · shares: Includes 1,424 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 356 shares on July 1, 2024, October 1, 2024, January 1, 2025 and April 1, 2025, if he is a director of the Company on those dates.

SEC source: 0000950170-24-063172 · ownership.xml · nonDerivative · entry 1

Gilmartin Kathleen A · CIK 0001741732 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,904

F1 · shares: Includes 1,424 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 356 shares on July 1, 2024, October 1, 2024, January 1, 2025 and April 1, 2025, if he is a director of the Company on those dates.

SEC source: 0000950170-24-063163 · ownership.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,424

F1 · shares: Includes 1,424 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 356 shares on July 1, 2024, October 1, 2024, January 1, 2025 and April 1, 2025, if he is a director of the Company on those dates.

SEC source: 0000950170-24-063151 · ownership.xml · nonDerivative · entry 2

HENDRICKSON CAREY P · CIK 0001482760 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,985

F1 · balance_after: Includes 13,930 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 1,438 shares on July 1, 2024, and 1,446 on October 1, 2024; 1,209 shares on January 1, 2025, 1,208 shares on April 1, 2025, July 1, 2025, October 1, 2025; 1,221 shares on January 1, 2026; 740 shares on April 1, 2026, July 1, 2026, October 1, 2026; 747 shares on January 1, 2027; and 506 shares on each of April 1, 2027, July 1, 2027, October 1, 2027 and 507 shares on Janaury 2028, if he is an Officer of the Company on those dates.

SEC source: 0000950170-24-063151 · ownership.xml · nonDerivative · entry 1

HENDRICKSON CAREY P · CIK 0001482760 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,043

SEC source: 0000950170-24-063106 · ownership.xml · nonDerivative · entry 1

HAM NANCY · CIK 0001124500 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,284

F1 · shares: Includes 1,424 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 356 shares on July 1, 2024, October 1, 2024, January 1, 2025 and April 1, 2025, if he is a director of the Company on those dates.

SEC source: 0000950170-24-061806 · ownership.xml · nonDerivative · entry 1

Binstein Richard · CIK 0001919840 · EVP Gen'l Counsel & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,895

F1 · price: The price reported ($106.34) is the weighted average price. The shares were sold in multiple transactions at prices ranging from $106.03 to $106.78 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 12,895 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 1,239 shares on each of July 1, 2024 and October 1, 2024; 1,241 shares on January 1, 2025; 1,045 shares on each April 1, 2025, July 1, 2025, and on October 1, 2025; 1,049 shares on January 1, 2026; 740 shares on each of April 1, 2026, July 1, 2026, October 1, 2026; 747 shares on January 1, 2027; and 506 shares on each of April 1, 2027, July 1, 2027, October 1, 2027; and 507 shares on January 1, 2028, if he is an employee of the Company on those dates.

SEC source: 0000950170-24-061197 · ownership.xml · nonDerivative · entry 1

KUNTZ EDWARD L · CIK 0001182168 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,280

F1 · price: The price reported ($107.57) is the weighted average price. The shares were sold in multiple transactions at prices ranging from $107.15 to $108.09 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0000950170-24-059855 · ownership.xml · nonDerivative · entry 1

Williams Eric Joseph · CIK 0001871391 · Co-Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,814

F1 · price: The price reported ($104.22) is the weighted average price. The shares were sold in multiple transactions at prices ranging from $104.00 to $105.00 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 14,622 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 1,408 shares on each of July 1, 2024 and October 1, 2024; 1,409 shares on January 1, 2025; 1,408 shares on April 1, 2025, 1,414 shares on July 1, 2025, 1,130 on October 1, 2025; 1,139 shares on January 1, 2026; 818 shares on each of April 1, 2026, July 1, 2026, October 1, 2026; 827 shares on January 1, 2027; and 506 shares on each of April 1, 2027, July 1, 2027, October 1, 2027; and 507 shares on January 1, 2028, if he is an employee of the Company on those dates.

SEC source: 0000950170-24-059850 · ownership.xml · nonDerivative · entry 1

REEVE GRAHAM D. · CIK 0001519948 · COO

10b5-1 filing: No plan indicated

Ownership: Indirect · Reeve Trust

Disclosed balance after: 6,970

F1 · price: The price reported ($105.46) is the weighted average price. The shares were sold in multiple transactions at prices ranging from $105.44 to $105.50 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0000950170-24-031674 · ownership.xml · nonDerivative · entry 2

HENDRICKSON CAREY P · CIK 0001482760 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,186

F1 · balance_after: Includes 15,368 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 1,438 shares on each of April 1, 2024, July 1, 2024 and 1,446 shares on October 1, 2024; 1,209 shares on January 1, 2025; 1,208 shares on each of April 1, 2025, July 1, 2025 and October 1, 2025; 1,221 shares on January 1, 2026; 740 shares on each of April 1, 2026, July 1, 2026, October 1, 2026; 747 shares on January 1, 2027; and 506 shares on each of April 1, 2027, July 1, 2027, October 1, 2027; and 507 shares on January 1, 2028, if he is an employee of the Company on those dates.

SEC source: 0000950170-24-031674 · ownership.xml · nonDerivative · entry 1

HENDRICKSON CAREY P · CIK 0001482760 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,974

SEC source: 0000950170-24-031651 · ownership.xml · nonDerivative · entry 1

Binstein Richard · CIK 0001919840 · EVP Gen'l Counsel & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,006

F1 · price: The price reported is a weighted average price ($106.55). The shares were sold in multiple transactions at prices ranging from $106.55 to $106.71 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 14,134 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 1,239 shares on each of April 1, 2024, July 1, 2024 and October 1, 2024; 1,241 shares on January 1, 2025; 1,045 shares on each of April 1, 2025, July 1, 2025, October 1, 2025; 1,049 shares on January 1, 2026; 740 shares on each of April 1, 2026, July 1, 2026, October 1, 2026; 747 shares on January 1, 2027; and 506 shares on each of April 1, 2027, July 1, 2027, October 1, 2027; and 507 shares on January 1, 2028, if he is an employee of the Company on those dates.

SEC source: 0000950170-24-031638 · ownership.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,000

F1 · balance_after: Includes 400 shares of restricted stock granted under the Company's equity plans. Restrictions will lapse as to the 400 shares on April 1, 2024 subject to the grantee's continued service as director of Company on those dates.

SEC source: 0000950170-24-031519 · ownership.xml · nonDerivative · entry 1

HAM NANCY · CIK 0001124500 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 860

F1 · balance_after: Includes 400 shares of restricted stock granted under the Company equity plans. Restrictions has lapse as to the 400 shares on April 1, 2024, subject to the grantee's continued service as director of Company on those dates.

SEC source: 0000950170-24-026491 · ownership.xml · nonDerivative · entry 1

REEVE GRAHAM D. · CIK 0001519948 · COO

10b5-1 filing: No plan indicated

Ownership: Indirect · Reeve Trust

Disclosed balance after: 6,902

F1 · price: This price is a weighted average price. The shares were sold in multiple transactions at prices ranging from $104.12 to $104.74 per share, both inclusive. The reporting person undertakes to provide U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set fort in this footnote to this Form 4.

SEC source: 0000950170-24-026469 · ownership.xml · nonDerivative · entry 2

Williams Eric Joseph · CIK 0001871391 · Co-Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,314

F1 · balance_after: Includes 16,030 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 1,408 shares on each of April 1, 2024, July 1, 2024 and October 1, 2024; 1,409 shares on January 1, 2025; 1,408 shares on April 1, 2025, 1,414 shares on July 1, 2025, 1,130 on October 1, 2025; 1,139 shares on January 1, 2026; 818 shares on each of April 1, 2026, July 1, 2026, October 1, 2026; 827 shares on January 1, 2027; and 506 shares on each of April 1, 2027, July 1, 2027, October 1, 2027; and 507 shares on January 1, 2028, if he is an employee of the Company on those dates.

SEC source: 0000950170-24-026469 · ownership.xml · nonDerivative · entry 1

Williams Eric Joseph · CIK 0001871391 · Co-Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,314

SEC source: 0000950170-24-026459 · ownership.xml · nonDerivative · entry 1

KUNTZ EDWARD L · CIK 0001182168 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,780

F1 · price: This price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $104.00 to $104.80 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 400 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares on April 1, 2024, if he is a director of the Company on those dates.

SEC source: 0000950170-24-022521 · ownership.xml · nonDerivative · entry 1

READING CHRISTOPHER J · CIK 0001270356 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,838

F1 · shares: Includes 16,200 shares, inclusive of those shares mentioned in note1, which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 15 equal installments with the first 1,012 shares on April 1, 2024 and thereafter with 1,012 shares on April 1, July 1, October 1 and Janaury 1 of each year with the final 1,017 shares lapsing on Janaury 1, 2028, if he is employed by the Company on those dates.

F2 · balance_after: Includes 36,500 shares, inclusive of those shares mentioned in Note 1, which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 3,587 shares on each of April 1, 2024, July 1, 2024 and October 1, 2024; 3,588 shares on January 1, 2025; 2,887 shares on each of April 1, 2025, July 1, 2024, October 1, 2025; 2,888 shares on January 1, 2026; 1,637 shares on each of April 1, 2026, July 1, 2026, October 1, 2026; 1,638 shares on January 1, 2027; and 1012 shares on each of April 1, 2027, July 1, 2026, October 1, 2027; and 1,017 shares on January 1, 2028, if he is an employee of the Company on those dates.

SEC source: 0000950170-24-022520 · ownership.xml · nonDerivative · entry 1

REEVE GRAHAM D. · CIK 0001519948 · COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,260

F1 · shares: The 8,100 shares of common stock were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 15 equal quarterly installments with the first 506 shares vesting on April 1, 2024 thereafter 506 shares on April 1, July 1, October 1 and January 1 of each year with the final 510 shares lapsong on Janaury 1, 2028 if he is employed by the Company on those dates.

F2 · balance_after: Includes 18,260 shares, inclusive of those shares mentioned in note1, which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 1,792 shares on each of April 1, 2024, July 1, 2024 and October 1, 2024; 1,793 shares on January 1, 2025; 1,442 shares on each of April 1, 2025, July 1, 2025, October 1, 2025; 1,459 shares on January 1, 2026; 818 shares on each of April 1, 2026, July 1, 2026, October 1, 2026; 827 shares on January 1, 2027; and 506 shares on each of April 1, 2027, July 1, 2027, October 1, 2027; and 507 shares on January 1, 2028, if he is an employee of the Company on those dates.

SEC source: 0000950170-24-022518 · ownership.xml · nonDerivative · entry 1

Williams Eric Joseph · CIK 0001871391 · Co-Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,814

F1 · shares: The 8,100 shares of common stock were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 15 equal quarterly installments with the first 506 shares vesting on April 1, 2024 thereafter 506 shares on April 1, July 1, October 1 and January 1 of each year with the final 510 shares lapsong on Janaury 1, 2028 if he is employed by the Company on those dates.

F2 · balance_after: Includes 16,030 shares, inclusive of those shares mentioned in note1, which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 1,408 shares on each of April 1, 2024, July 1, 2024 and October 1, 2024; 1,409 shares on January 1, 2025; 1,408 shares on each of April 1, 2025, 1,414 shares on July 1, 2025, 1,130 on October 1, 2025; 1,139 shares on January 1, 2026; 818 shares on each of April 1, 2026, July 1, 2026, October 1, 2026; 827 shares on January 1, 2027; and 506 shares on each of April 1, 2027, July 1, 2027, October 1, 2027; and 507 shares on January 1, 2028, if he is an employee of the Company on those dates.

SEC source: 0000950170-24-022516 · ownership.xml · nonDerivative · entry 1

Binstein Richard · CIK 0001919840 · EVP Gen'l Counsel & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,006

F1 · shares: The 8,100 shares of common stock were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 15 equal quarterly installments with the first 506 shares vesting on April 1, 2024 thereafter 506 shares on April 1, July 1, October 1 and January 1 of each year with the final 510 shares lapsong on Janaury 1, 2028 if he is employed by the Company on those dates.

F2 · balance_after: Includes 14,134 shares, inclusive of those shares mentioned in note1, which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 1,239 shares on each of April 1, 2024, July 1, 2024 and October 1, 2024; 1,241 shares on January 1, 2025; 1,045 shares on each of April 1, 2025, July 1, 2025, October 1, 2025; 1,049 shares on January 1, 2026; 740 shares on each of April 1, 2026, July 1, 2026, October 1, 2026; 747 shares on January 1, 2027; and 506 shares on each of April 1, 2027, July 1, 2027, October 1, 2027; and 507 shares on January 1, 2028, if he is an employee of the Company on those dates.

SEC source: 0000950170-24-022515 · ownership.xml · nonDerivative · entry 1

HENDRICKSON CAREY P · CIK 0001482760 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,986

F1 · shares: The 8,100 shares of common stock were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 15 equal quarterly installments with the first 506 shares vesting on April 1, 2024 thereafter 506 shares on April 1, July 1, October 1 and January 1 of each year with the final 510 shares lapsong on Janaury 1, 2028 if he is employed by the Company on those dates.

F2 · balance_after: Includes 15,368 shares, inclusive of those shares mentioned in note1, which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 1,438 shares on each of April 1, 2024, July 1, 2024 and 1,446 shares on October 1, 2024; 1,209 shares on January 1, 2025; 1,208 shares on each of April 1, 2025, July 1, 2025 and October 1, 2025; 1,221 shares on January 1, 2026; 740 shares on each of April 1, 2026, July 1, 2026, October 1, 2026; 747 shares on January 1, 2027; and 506 shares on each of April 1, 2027, July 1, 2027, October 1, 2027; and 507 shares on January 1, 2028, if he is an employee of the Company on those dates.

SEC source: 0001209191-23-058676 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,400

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.11 to $92.79, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 800 shares of restricted stock granted under the Company equity plans. Restrictions lapse as to 400 shares on each of January 1, 2024 and April 1, 2024, subject to the grantee's continued service as a director of the Company on those dates.

SEC source: 0001209191-23-057988 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,570

F1 · balance_after: Includes 800 shares of restricted stock granted under the Company equity plans. Restrictions lapse as to 400 shares on each of January 1, 2024 and April 1, 2024, subject to the grantee's continued service as a director of the Company on those dates.

SEC source: 0001209191-23-055567 · doc4.xml · nonDerivative · entry 2

REEVE GRAHAM D. · CIK 0001519948 · COO

10b5-1 filing: No plan indicated

Ownership: Indirect · Reeve Trust

Disclosed balance after: 7,801

F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.02 to $87.54, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-23-055080 · doc4.xml · nonDerivative · entry 1

Gilmartin Kathleen A · CIK 0001741732 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,480

F1 · price: The price reported is the weighted average price. The shares were purchased in multiple transactions at prices ranging from $82.32 to $82.35 per share both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of it shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 800 shares of restricted stock granted under the Company equity plans. Restrictions lapse as to 400 shares lapsed on each of January 1, 2024 and April 1, 2023, if she is a director of the Company on those dates.

SEC source: 0001209191-23-046028 · doc4.xml · nonDerivative · entry 1

HAM NANCY · CIK 0001124500 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,360

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $105.72 to $106.28, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 1,200 shares of common stock that were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares on October 1, 2023, January 1, 2024 and April 1, 2024, if she is a director of the Company on those dates.